Immune Globulin Subcutaneous 16.5% in the Treatment of Primary Immunodeficiency: A Two-Year Multicenter Analysis

Presented at AAAAI 2024

Authors:
Richard F. Herrscher, MD, FACAAI
Jeffrey W. Langford, MD, AE-C
Precious A. Anyanwu, PharmD, PhD
Lucinda J. Van Anglen, PharmD